All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
AUGMENT-101: Phase II results of revumenib in NPM1-mutated R/R AML
Results from the phase II portion of the AUGMENT-101 trial (NCT04065399) evaluating the efficacy and safety of revumenib, a potent selective menin inhibitor, with or without a CYP3A4 inhibitor, in 84 patients with NPM1-mutated (NPM1m) relapsed/refractory (R/R) acute myeloid leukemia (AML) were published by Arellano et al. in Blood.
Key data: Among the efficacy-evaluable patients (n = 64), the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 23.4% (p = 0.0014), with a composite CR (CRc) rate of 29.7%. The overall response rate (ORR) was 46.9%, and the median duration of response (DoR) was 4.7 months. Grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 91.7% of all patients, while Grade ≥3 QTcF prolongation occurred in 22.6%. Treatment-related discontinuations were reported in 4.8%.
Key learning: Revumenib demonstrated a clinically meaningful benefit and was well tolerated in patients with NPM1m R/R AML, suggesting its potential to significantly improve outcomes in this high-risk subgroup.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your clinical practice, how do you perceive the efficacy of ivosidenib (Ivo) + azacitidine (Aza) relative to venetoclax (Ven) + Aza for the treatment of patients with IDH1-mutated AML?
